{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:49:21Z","timestamp":1787017761253,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["fertstertreports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["F&S Reports"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.xfre.2023.02.009","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T13:09:16Z","timestamp":1677244156000},"page":"56-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S","title":["Ganirelix and the prevention of premature luteinizing hormone surges"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9127-8013","authenticated-orcid":false,"given":"Bernadette","family":"Mannaerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xfre.2023.02.009_bib1","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/humrep\/15.9.1882","article-title":"Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor","volume":"15","author":"Mannaerts","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfre.2023.02.009_bib2","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1093\/humrep\/13.11.3023","volume":"13","year":"1998","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfre.2023.02.009_bib3","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1093\/humrep\/14.9.2242","article-title":"High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles","volume":"14","author":"Kol","year":"1999","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfre.2023.02.009_bib4","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1093\/humrep\/dei243","article-title":"Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles","volume":"20","author":"Simon","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfre.2023.02.009_bib5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0015-0282(99)00413-6","article-title":"Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon\/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers","volume":"72","author":"Obery\u00e9","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfre.2023.02.009_bib6","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0015-0282(99)00414-8","article-title":"Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon\/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers","volume":"72","author":"Obery\u00e9","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfre.2023.02.009_bib7","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/humrep\/15.7.1490","volume":"15","author":"Borm","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfre.2023.02.009_bib8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0015-0282(00)01638-1","article-title":"Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation","volume":"75","author":"Fluker","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfre.2023.02.009_bib9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/humrep\/16.4.644","article-title":"Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation","volume":"16","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfre.2023.02.009_bib10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/humupd\/dml001","article-title":"GnRH antagonists in ovarian stimulation for IVF","volume":"12","author":"Tarlatzis","year":"2006","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.xfre.2023.02.009_bib11","article-title":"Gonadotrophin\u2013releasing hormone antagonists for assisted reproductive technology","volume":"4","author":"Al-Inany","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xfre.2023.02.009_bib12","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/humrep\/dew051","article-title":"Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF\/ICSI cycles","volume":"31","author":"Toftager","year":"2016","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfre.2023.02.009_bib13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/humupd\/dmx017","article-title":"GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type","volume":"23","author":"Lambalk","year":"2017","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.xfre.2023.02.009_bib14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.rbmo.2014.05.008","article-title":"GnRHa trigger for final oocyte maturation: is HCG trigger history?","volume":"29","author":"Humaidan","year":"2014","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.xfre.2023.02.009_bib15","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.rbmo.2015.12.007","article-title":"GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis","volume":"32","author":"Engmann","year":"2016","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.xfre.2023.02.009_bib16","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1210\/endo.140.8.6899","article-title":"The role of gonadotropin-releasing hormone in murine preimplantation embryonic development","volume":"140","author":"Raga","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.xfre.2023.02.009_bib17","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/humrep\/der251","article-title":"An OHSS-Free Clinic by segmentation of IVF treatment","volume":"26","author":"Devroey","year":"2011","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfre.2023.02.009_bib18","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/humrep\/15.9.1965","volume":"15","author":"Itskovitz-Eldor","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfre.2023.02.009_bib19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1210\/jcem.87.2.8197","article-title":"Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in\u00a0vitro fertilization","volume":"87","author":"Fauser","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfre.2023.02.009_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.fertnstert.2003.05.032","article-title":"Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome","volume":"81","author":"Kol","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfre.2023.02.009_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1477-7827-11-90","article-title":"Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation","volume":"11","author":"Frattarelli","year":"2013","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.xfre.2023.02.009_bib22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in\u00a0vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Andersen","year":"2017","journal-title":"Fertil Steril"}],"container-title":["F&S Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266633412300017X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266633412300017X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T12:02:44Z","timestamp":1738497764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266633412300017X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S266633412300017X"],"URL":"https:\/\/doi.org\/10.1016\/j.xfre.2023.02.009","relation":{},"ISSN":["2666-3341"],"issn-type":[{"value":"2666-3341","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ganirelix and the prevention of premature luteinizing hormone surges","name":"articletitle","label":"Article Title"},{"value":"F&S Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xfre.2023.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}